Breakfast will be served. Seating for these sessions is available on a first-come, firstservedbasis. Admittance is based on availability and is not guaranteed. Please plan toarrive early to ensure a seat. Breakfast will only be available until 8 A.M.
Research into tardive dyskinesia (TD) pathophysiology and treatment targetshas led to the advancement of vesicular monoamine transporter 2 (VMAT2)inhibitors, with one agent recently approved by the FDA and the other grantedbreakthrough therapy designation. Key differences in the pharmacokinetic/pharmacodynamic properties of these newer agents will be examined, as wellas clinical outcome data from the ARM-TD, AIM- TD, KINECT-3, the ongoingKINECT-4, and other clinical trials.
Supported by an educational grant from Teva Pharmaceuticals.
Sunday September 17, 2017 7:00am - 9:00am CDT
La Nouvelle Orleans ABThe New Orleans Ernest N. Morial Convention Center, 900 Convention Center Boulevard New Orleans, LA 70130